The company received approval for – the Confient implantable cardioverter defibrillator (ICD), which helps protect patients at risk of sudden cardiac death, the Livian cardiac resynchronization therapy defibrillator (CRT-D), which provides cardiac resynchronization and defibrillation therapies in one device, and for the upgraded Latitude Patient Management System, with enhanced remote monitoring capabilities.
Jim Tobin, president and CEO of Boston Scientific, said: “Our Cardiac Rhythm Management team is refocused on delivering therapy systems that meet physicians’s needs for safety, reliability and better patient outcomes.”